PGXL, AutoGenomics Partner on Personalized Medicine
April 01, 2011
PGXL, AutoGenomics Partner on Personalized Medicine
PGXL plans to use the Infiniti Warfarin assay and the CYP450 assay, both of which have been cleared by the US Food and Drug Administration, as well as the Infiniti KRAS-BRAF test.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- SQI Buying Microarray Firm Scienion for $15.6M, and Stock
July 5, 2011 / GenomeWeb Daily News - AutoGenomics Launches Familial Mediterranean Fever Panel, Plans FDA Submission
January 25, 2011 / BioArray News - Mizuho Initiates Coverage of Affymetrix with Outperform Rating
August 26, 2011 / GenomeWeb Daily News - Researchers Map CNVs in Children with Developmental Delays
August 15, 2011 / GenomeWeb Daily News - Diagnostic Revenues Drive up CombiMatrix Q2 Revenues 31 Percent
August 10, 2011 / GenomeWeb Daily News